Non-alcoholic fatty liver disease surgery
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease surgery On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease surgery |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
|
Risk calculators and risk factors for Non-alcoholic fatty liver disease surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Surgery is not the first-line treatment option for patients with non- Alcoholic fatty liver disease (NAFLD). However, gastric bypass surgery is recommended in patients with non-alcoholic fatty liver disease whose BMI is greater than 40 who psychologically stable and failed medical therapy.
Surgery
Indications
- Patients with NAFLD and BMI greater than 40 who psychologically stable
- In patients who failed medical therapy.
Surgical options
- The most common procedures are adjustable gastric banding and the Roux-en-Y bypass.[1]
- A Y-shaped section of the i bum is attached to the pouch so that food bypasses the duodenum and proximal section of the jejunum.
- A laparoscopic sleeve gastrectomy may be a secure and powerful treatment of weight problems in adult patients. Significant and sustained weight reduction results in the improvement NAFLD.[2][3]
- The size of the stomach is reduced either by stapling or banding, creating a small pouch, assisting with weight loss by inducing
- Earlier satiety
- Reducing caloric intake
- Decreasing absorptive capacity
- The feasibility of liver transplantation depends on the stage of NAFLD at diagnosis.NAFLD is emerging as the second most common cause for liver transplant.[4][5]
- Indication 1 End stage liver-disease
- Indication 2 Hepatocellular carcinoma (HCC) are the two most important indications for the liver transplant.
- Outcome : After liver transplanation patients with or without NASH may survive 1,3 and 5 years and are increasinly at risk for cardio vascular risks.[6]
Complications
- Early complications include:
- Late complications include
References
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
- ↑ Boscolo M, Féry F, Cnop M (2017). "Beneficial Outcomes of Sleeve Gastrectomy in a Morbidly Obese Patient With Bardet-Biedl Syndrome". J Endocr Soc. 1 (4): 317–322. doi:10.1210/js.2017-00071. PMID 29264490.
- ↑ Colquitt JL, Pickett K, Loveman E, Frampton GK (2014). "Surgery for weight loss in adults". Cochrane Database Syst Rev (8): CD003641. doi:10.1002/14651858.CD003641.pub4. PMID 25105982.
- ↑ Germani G, Becchetti C (2017). "Liver transplantation for non-alcoholic fatty liver disease". Minerva Gastroenterol Dietol. doi:10.23736/S1121-421X.17.02467-9. PMID 29249127.
- ↑ Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A (2017). "Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes". Dig. Dis. Sci. 62 (10): 2915–2922. doi:10.1007/s10620-017-4684-x. PMID 28744836.
- ↑ Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y (2014). "Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis". Clin. Gastroenterol. Hepatol. 12 (3): 394–402.e1. doi:10.1016/j.cgh.2013.09.023. PMID 24076414.